Breaking News

Arran Chemical Company Completes Stage II of its Strategic Plan ADAPT

The company has completed a multi-million Euro expansion of its manufacturing capacity and deployment of next ...

Biogen and Samsung Bioepis launch Imraldi in Europe

The product is the third anti-TNF biosimilar developed by Samsung Bioepis to be commercialised by Biogen across Europe

SPI Pharma launches Mannogem XL mannitol

Enabling the production of difficult-to-compress and problematic formulations

Preparing PIs for post EU-FMD success

Ian Haynes of Excellis Europe explains how the company’s unique approach to enabling collaboration between parallel ...

ACG group rebrands under single new identity

The integrated pharma manufacturing group consolidates its portfolio of businesses and regional brands into four ...

Almac Group expands existing North Carolina facility

The CDMO has invested in its clinical services and diagnostic service capabilities

Serialisation and data connectivity: Part I

The new wrinkle in your supply chain

PCI announces new facility dedicated to clinical trial returns

Continued investment at Bridgend site enables capacity expansion for segregated space in support of the return of ...

CPhI Worldwide announces winners of fifteenth Pharma Awards

The full list of winners from the annual 2018 CPhI Pharma Awards has been released

The Falsified Medicines Directive: clarification for wholesalers, distributors and logistics partners

The Falsified Medicines Directive (FMD) 2011/62/EU comes into force on 9 February 2019

A grandmaster’s approach to successful tableting

Tableting is a fundamental unit operation in the production of pharmaceutical oral solid dosage forms. Despite its long ...

Why risk it? FMD is not going away! Are you ready?

The Falsified Medicines Directive (FMD) imposes strict serialisation requirements on pharmaceutical manufacturers, ...

Staying secure in the smart era

Three rules for cyber security

Merck offers rhabdovirus-free insect platform for viral vaccines and gene therapy development

This will be the first non-mammalian cell line in Merck’s cell culture portfolio, allowing customers worldwide access ...